Bringing awareness to Triple Negative Breast Cancer.
Impact
The resolution seeks to promote education about triple negative breast cancer, highlighting the disparities in mortality rates among different racial groups, especially Black and Hispanic women. Evidence presented in the text indicates these groups are historically less likely to receive guideline-adherent care, contributing to worse health outcomes. By endorsing this resolution, the Indiana House of Representatives aims to enhance community awareness and push for systemic changes needed to tackle these inequities in the healthcare system.
Summary
HR0029, known as the resolution to bring awareness to Triple Negative Breast Cancer, addresses a significant health concern that disproportionately affects various demographic groups, particularly women of color and those with socio-economic disadvantages. The bill emphasizes the need for increased awareness regarding this specific type of breast cancer, which accounts for a notable percentage of breast cancer cases diagnosed annually in the United States. With its aggressive nature and limited treatment options, triple negative breast cancer remains a challenge for healthcare practitioners and patients alike.
Contention
While the resolution primarily calls for awareness and educational initiatives, potential contention may arise around funding and implementation of programs aimed at improving access to screening and care for underserved populations. Some legislators and advocacy groups may argue about the efficiency and sufficiency of proposed measures to address the root causes of disparities in healthcare access and outcomes for triple negative breast cancer patients. Discussions may also center on the allocation of resources to support education and awareness compared to providing direct assistance for medical care.
Triple-Negative Breast Cancer Research and Education Act of 2023 This bill requires research and education activities related to triple-negative breast cancer. The cells of these breast cancers are negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so they do not respond to hormonal therapy medicines or medicines that target the HER2 protein receptors. Specifically, the National Institutes of Health must conduct and support research into the disease. Additionally, the Centers for Disease Control and Prevention and the Health Resources and Services Administration must develop information about triple-negative breast cancer, including information regarding the elevated risk for minority women, for the public and for health care providers.